iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Cell types differentiated from induced pluripotent stem cells (iPSCs) are frequently arrested in their development program, more closely resembling a fetal rather than an adult phenotype, potentially limiting their utility for downstream clinical applications. The fetal phenotype of iPSC‐derived den...
Κύριοι συγγραφείς: | Horton, C, Davies, TJ, Lahiri, P, Sachamitr, P, Fairchild, PJ |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Wiley
2019
|
Παρόμοια τεκμήρια
-
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
ανά: Sachamitr, P, κ.ά.
Έκδοση: (2012) -
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
ανά: Bravo, M, κ.ά.
Έκδοση: (2021) -
Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset
ανά: Sachamitr, P, κ.ά.
Έκδοση: (2018) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
ανά: Hanif, Javanmard Khameneh
Έκδοση: (2011) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.
ανά: Hanif Javanmard Khameneh
Έκδοση: (2014)